Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(17%)

Phase Distribution

Ph phase_2
6
100%

Phase Distribution

0

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
6(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 5 finished

Non-Completion Rate

100.0%

5 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Terminated(5)
Other(1)

Detailed Status

Withdrawn4
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 26 (100.0%)

Trials by Status

withdrawn467%
terminated117%
unknown117%

Recent Activity

0 active trials
Showing 5 of 6
withdrawnphase_2

Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise

NCT04992247
terminatedphase_2

Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress

NCT04903327
unknownphase_2

Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress

NCT04905836
withdrawnphase_2

Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome

NCT04909879
withdrawnphase_2

Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress

NCT04728698
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04992247Phase 2

Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise

Withdrawn
NCT04903327Phase 2

Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress

Terminated
NCT04905836Phase 2

Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress

Unknown
NCT04909879Phase 2

Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome

Withdrawn
NCT04728698Phase 2

Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress

Withdrawn
NCT04909892Phase 2

Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise

Withdrawn

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6